MX2020005007A - Combinaciones farmaceuticas y metodos para el tratamiento de diabetes y trastornos asociados. - Google Patents

Combinaciones farmaceuticas y metodos para el tratamiento de diabetes y trastornos asociados.

Info

Publication number
MX2020005007A
MX2020005007A MX2020005007A MX2020005007A MX2020005007A MX 2020005007 A MX2020005007 A MX 2020005007A MX 2020005007 A MX2020005007 A MX 2020005007A MX 2020005007 A MX2020005007 A MX 2020005007A MX 2020005007 A MX2020005007 A MX 2020005007A
Authority
MX
Mexico
Prior art keywords
diabetes
treatment
methods
associated disorders
pharmaceutical combinations
Prior art date
Application number
MX2020005007A
Other languages
English (en)
Inventor
Philip Myers Heyward
Alexander Tups
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017904756A external-priority patent/AU2017904756A0/en
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Publication of MX2020005007A publication Critical patent/MX2020005007A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere a se refiere a composiciones farmacéuticas que comprenden buteina (BTN) y sulfuretina (SFL) y/o isoliquiritigenina (ILQ) o sales, tautómeros, solvatos y/o derivados farmacéuticamente aceptables de estas. La invención se refiere además al uso de tales composiciones en el tratamiento de diabetes o una enfermedad, afección y/o trastorno asociado tal como prediabetes y/o deterioro de la regulación de la glucosa inducido por la dieta, y el uso de composiciones que comprenden solo sulfuretina (SFL) o isoliquiritigenina (ILQ) para los tratamientos.
MX2020005007A 2017-11-24 2018-11-26 Combinaciones farmaceuticas y metodos para el tratamiento de diabetes y trastornos asociados. MX2020005007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017904756A AU2017904756A0 (en) 2017-11-24 Pharmaceutical combinations and methods of treatment
PCT/NZ2018/050169 WO2019103629A1 (en) 2017-11-24 2018-11-26 Pharmaceutical combinations and methods for the treatment of diabetes and associated disorders

Publications (1)

Publication Number Publication Date
MX2020005007A true MX2020005007A (es) 2021-01-15

Family

ID=66631686

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005007A MX2020005007A (es) 2017-11-24 2018-11-26 Combinaciones farmaceuticas y metodos para el tratamiento de diabetes y trastornos asociados.

Country Status (9)

Country Link
US (1) US11738001B2 (es)
EP (1) EP3713561A4 (es)
JP (1) JP7434154B2 (es)
KR (1) KR20200136360A (es)
CN (1) CN111386111A (es)
AU (1) AU2018370761A1 (es)
CA (1) CA3085758A1 (es)
MX (1) MX2020005007A (es)
WO (1) WO2019103629A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112716966B (zh) * 2021-02-03 2022-05-03 浙江诺得药业有限公司 一种恩格列净药用组合物及其制备方法
CN114632092B (zh) * 2022-05-17 2022-08-23 北京第一生物化学药业有限公司 睾丸片在制备具有降糖活性的药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005011671A1 (en) 2003-08-05 2005-02-10 Lifetree Biotech Co., Ltd. Use of flavonoids for preventing and treating gastritis and gastric ulcer
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
CN101176786A (zh) 2006-11-08 2008-05-14 中国科学院上海生命科学研究院 增加胰岛素敏感性的方法和组合物
JP2008247839A (ja) * 2007-03-30 2008-10-16 Toyobo Co Ltd カルコン配糖体を含む抗酸化剤
KR100926454B1 (ko) 2007-06-05 2009-11-13 한국과학기술연구원 옻나무 추출물, 이의 분획물 또는 상기 분획물에서 분리한화합물을 포함하는 당뇨병 합병증 예방 및 치료용 조성물
KR101159442B1 (ko) 2010-04-26 2012-06-22 전북대학교산학협력단 옻나무로부터 분리된 설퍼레틴을 유효성분으로 포함하는 제１형 당뇨병 예방 및 치료용 조성물 및 이를 포함하는 건강식품
US20130338178A1 (en) * 2011-02-02 2013-12-19 The Trustees Of Princeton University Sirtuin modulators as inhibitors of cytomegalovirus
WO2015158836A1 (en) 2014-04-16 2015-10-22 Vital Solutions Swiss Ag Mangifera indica as a sirtuin 1 activating agent
AU2015100662A4 (en) 2015-05-20 2015-06-11 Macau University Of Science And Technology Isoliquiritigenin Suppresses human T lymphocyte activation via targeting on cysteine 46 of IKBA Kinase

Also Published As

Publication number Publication date
JP7434154B2 (ja) 2024-02-20
CA3085758A1 (en) 2019-05-31
US20200289453A1 (en) 2020-09-17
AU2018370761A1 (en) 2020-05-28
CN111386111A (zh) 2020-07-07
EP3713561A4 (en) 2021-08-04
EP3713561A1 (en) 2020-09-30
WO2019103629A1 (en) 2019-05-31
KR20200136360A (ko) 2020-12-07
JP2021504340A (ja) 2021-02-15
US11738001B2 (en) 2023-08-29

Similar Documents

Publication Publication Date Title
MX2020010484A (es) Derivados de heterociclilos sustituidos como inhibidores de cdk.
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MY195002A (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12020551425A1 (en) Rimegepant for cgrp related disorders
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2014194254A8 (en) Treatment of cancers using pi3 kinase isoform modulators
MY187047A (en) Selective pyy compounds and uses thereof
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2017004772A (es) Composiciones y métodos para la administración fisiológica utilizando cannabidiol.
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
CL2019000625A1 (es) Combinación de agonistas de fxr.
MX2020005007A (es) Combinaciones farmaceuticas y metodos para el tratamiento de diabetes y trastornos asociados.
EP4041209A4 (en) TRANSDERMAL COMPOSITIONS CONTAINING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF SEIZURE DISORDERS
WO2011050008A9 (en) Combination therapy comprising administration of an amylinomimetic and a pyy peptidomimetic for effecting weight loss and for treating obesity and related metabolic conditions and disorders
EP3922264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
TN2016000497A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
WO2019014322A8 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASES
EP3903789A4 (en) THERAPEUTIC MEDICINE FOR A DISEASE ACCOMPANIED BY DISORDERS IN CELLS OF THE RETINAL SYSTEM OR RETINA TISSUE
BR112017014295A2 (pt) composição farmacêutica.
EP3844168A4 (en) COMBINATION DRUG PREPARATIONS FOR THE TREATMENT OF PATIENTS WITH CARDIOVASCULAR DISEASE AND ASSOCIATED CONDITIONS
EP3795170A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING CCN5 USED AS AN EFFECTIVE INGREDIENT FOR THE PREVENTION OR TREATMENT OF RETINAL DISEASE
MX2018012952A (es) Composicion oftalmica que comprende una combinacion sinergica de glucogeno y acido hialuronico o sal del mismo.